Case Note & Summary
The case involved an appeal by M/s. Medicamen Biotech Ltd. against proceedings initiated by a Drug Inspector for alleged non-conformance of their drug, Enalapril Maleate tablets, to prescribed standards. The drug was manufactured under license and had been tested by an independent laboratory before being sold. Following a sample collection by the Drug Inspector in June 2000, the test report declared the drug sub-standard, leading to a show-cause notice issued to the appellants in August 2001. The appellants disputed the report and requested re-testing, but their requests were not acted upon. The complaint was filed in July 2002, shortly before the drug's shelf life expired. The appellants challenged the proceedings in the Calcutta High Court, which dismissed their petition, stating that the allegations indicated the commission of an offence. The Supreme Court examined the legal provisions under the Drugs and Cosmetics Act, particularly Sections 25(3) and 25(4), which outline the rights of a manufacturer to contest a Government Analyst's report. The court found that the appellants had indeed expressed their intention to contest the report within the stipulated time frame, and thus, they were deprived of their right to have the sample re-tested. The court noted that the timing of the complaint filing was problematic, as it was close to the expiry of the drug's shelf life, and there was no justification for the delay in sending the sample for re-testing. Ultimately, the Supreme Court quashed the proceedings against the appellants, allowing their appeal.
Headnote
A) Drugs and Cosmetics Act - Sample Testing Procedures - Right to Re-Test - Drugs and Cosmetics Act, 1940, Sections 25(3), 25(4) - The appellants contended that they were denied the opportunity to have the fourth sample tested by the Central Drugs Laboratory despite their repeated requests to contest the Government Analyst's report. The court held that the appellants had indeed expressed their intention to adduce evidence against the report, thus necessitating the quashing of the proceedings against them (Paras 10-11).
Issue of Consideration
Whether the appellants were deprived of their right to have the fourth sample tested by the Central Drugs Laboratory under the Drugs and Cosmetics Act, 1940.
Final Decision
The Supreme Court allowed the appeal and quashed the proceedings against the appellants, finding that they were deprived of their right to have the fourth sample tested by the Central Drugs Laboratory.
Law Points
- Drug quality standards
- sample testing procedures
- conclusive evidence
- right to re-test
- statutory obligations
